Minirin (Desmopressin Acetate)

Desmopressin, the active ingredient in Minirin, is a vasopressin analog presented as an injectable solution for intramuscular, intravenous, and subcutaneous use. It treats central diabetes insipidus, nocturnal enuresis, and bleeding disorders such as von Willebrand disease.

GNH USA supplies Minirin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Desmopressin acts on the antidiuretic hormone pathway to manage conditions characterized by excessive urine output or bleeding disorders.

Central diabetes insipidus: reduces urine volume and concentrates urine. Nocturnal enuresis: decreases nighttime urine production, helping control bedwetting. Von Willebrand disease: raises plasma von Willebrand factor and factor VIII levels, improving haemostatic function.

Desmopressin may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Nausea - Abdominal cramps - Flushing - Mild hyponatremia

Serious or Rare Side Effects: - Severe hyponatremia with seizures or coma - Water intoxication leading to cerebral edema - Allergic reactions such as rash or anaphylaxis - Thrombotic events in predisposed patients - Hypertension due to fluid overload

When prescribing desmopressin, clinicians should observe several precautionary measures to minimise risk. - Monitor serum sodium: check electrolytes before initiation and periodically during therapy. - Adjust dose in renal impairment: reduced clearance may increase risk of hyponatremia. - Use cautiously in elderly: age‑related renal function decline heightens fluid‑balance concerns. - Avoid in uncontrolled hypertension: fluid retention can exacerbate blood pressure. - Review concomitant medications: diuretics or NSAIDs may potentiate water retention. - Store at room temperature: keep in the original pack, protect from moisture and light.

Desmopressin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Other antidiuretic agents (e.g., ADH analogues): additive risk of hyponatremia. - Thiazide diuretics: potentiate water retention and hyponatremia. - Concomitant use with carbamazepine: may reduce desmopressin effectiveness.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase antidiuretic effect and hyponatremia risk. - ACE inhibitors or ARBs: can enhance fluid retention, requiring sodium monitoring. - CYP450 inducers (e.g., phenytoin, rifampin): may lower plasma levels of desmopressin. - Anticoagulants: monitor bleeding risk when using desmopressin for haemostatic purposes.